Biotech Values

[DewDiligence]

HBV notes from 3Q06 GILD CC:

The number of U.S. patients treated by all HBV drugs (Hepsera, Baraclude, Lamivudine) has grown by 30% year-over-year from 33K to 43K. However, this still represents a tiny fraction of the disease prevalence of 1.2M and the symptomatic disease prevalence of 350K. Moreover, these numbers are expanding rapidly from Asian immigration.

Global 3Q06 Hepsera sales were $55M (+18% Y-o-Y).

Hepsera’s Rx market share is >50% in the U.S. and 37% in Europe, where Lamivudine is amazingly still the market leader.

Note: BMY reports 3Q06 Baraclude sales next week.